SCHEMBL5156573

SCHEMBL5156573

COc1cc([C@@H]2CCCN2C(=O)OCC2c3ccccc3-c3ccccc32)ccc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
FABP5 Q01469 1/20 0.43
CFB P00751 1/20 0.43
ROCK2 O75116 4/20 0.42
SCD5 Q86SK9 1/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14558811 0.82 ROCK2 (0.46) HSP90AA1HSP90AB1FABP5CFBROCK2
SCHEMBL31370488 0.81 ROCK2 (0.45) FABP5ROCK2SCD5GAAALDH1A1
Acetic Acid SCHEMBL27570248 0.79 ROCK2 (0.44) ROCK2SCD5ALDH1A1TMEM97SIGMAR1
SCHEMBL5150024 0.79 TMEM97 (0.41) FABP5ROCK2SCD5TMEM97SIGMAR1
SCHEMBL5150021 0.79 TMEM97 (0.41) FABP5ROCK2SCD5TMEM97SIGMAR1
SCHEMBL14558766 0.78 TMEM97 (0.48) HSP90AA1HSP90AB1FABP5CFBTMEM97
SCHEMBL5149804 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CFBROCK2HTTMAPT
SCHEMBL5149814 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CFBROCK2HTTMAPT
SCHEMBL14558770 0.78 TMEM97 (0.42) HSP90AA1HSP90AB1FABP5SCD5TMEM97
SCHEMBL14558757 0.77 TMEM97 (0.47) SMN1; SMN2FABP5TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 HSP90AA1 1298/4885HSP90AB1 1387/4885SMN1; SMN2 4151/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 HSP90AA1 1574/4885HSP90AB1 1623/4885SMN1; SMN2 4245/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 HSP90AA1 1255/4885HSP90AB1 1368/4885SMN1; SMN2 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.